Deregulated miRNAs in hereditary breast cancer revealed a role for miR-30c in regulating KRAS oncogene

PLoS ONE

Volumn 7, Issue 6, 2012, Pages

  Tanic, Miljana ^a   Yanowsky, Kira ^a,b   Rodriguez Antona, Cristina ^a   Andrés, Raquel ^c   Márquez Rodas, Iván ^d   Osorio, Ana ^a,b   Benitez, Javier ^a,b   Martinez Delgado, Beatriz ^a,b  

^a Centro Nacional de Investigaciones Oncológicas   (Spain)

^b CENTRO DE INVESTIGACIÓN BIOMÉDICA EN RED DE ENFERMEDADES RARAS CIBERER   (Spain)

^c HOSPITAL CLÍNICO UNIVERSITARIO LOZANO BLESA   (Spain)

^d HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

MICRORNA; MICRORNA 100; MICRORNA 125A; MICRORNA 205; MICRORNA 30C; MITOGEN ACTIVATED PROTEIN KINASE; STRESS ACTIVATED PROTEIN KINASE 1; UNCLASSIFIED DRUG; KRAS PROTEIN, HUMAN; LUCIFERASE; MIRN30 MICRORNA, HUMAN; ONCOPROTEIN; PRIMER DNA; RAS PROTEIN;

3' UNTRANSLATED REGION; ARTICLE; BINDING SITE; BREAST CANCER; CANCER CELL; CANCER GROWTH; CELL PROLIFERATION; CLINICAL ARTICLE; CONTROLLED STUDY; DOWN REGULATION; FAMILIAL CANCER; FEMALE; GENE EXPRESSION PROFILING; HUMAN; HUMAN CELL; HUMAN TISSUE; MICROARRAY ANALYSIS; ONCOGENE K RAS; PROTEIN EXPRESSION; PROTEIN FUNCTION; QUANTITATIVE ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; TUMOR GROWTH; UBIQUITINATION; BREAST TUMOR; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; REAL TIME POLYMERASE CHAIN REACTION;

BREAST NEOPLASMS; DNA PRIMERS; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LUCIFERASES; MICROARRAY ANALYSIS; MICRORNAS; PROTO-ONCOGENE PROTEINS; RAS PROTEINS; REAL-TIME POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION;

EID: 84862219230     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0038847     Document Type: Article

References (37)

1. Bradbury AR, Olopade OI, (2007) Genetic susceptibility to breast cancer. Rev Endocr Metab Disord 8: 255-267.
2. Palacios J, Robles-Frias MJ, Castilla MA, Lopez-Garcia MA, Benitez J, (2008) The molecular pathology of hereditary breast cancer. Pathobiology 75: 85-94.
3. Perou CM, Sorlie T, Eisen MB, van de Rijn M, Jeffrey SS, et al. (2000) Molecular portraits of human breast tumours. Nature 406: 747-752.
4. Hedenfalk I, Duggan D, Chen Y, Radmacher M, Bittner M, et al. (2001) Gene-expression profiles in hereditary breast cancer. The New England journal of medicine 344: 539-548.
5. Liu CG, Calin GA, Meloon B, Gamliel N, Sevignani C, et al. (2004) An oligonucleotide microchip for genome-wide microRNA profiling in human and mouse tissues. Proc Natl Acad Sci U S A 101: 9740-9744.
6. Calin GA, Croce CM, (2006) MicroRNA-cancer connection: the beginning of a new tale. Cancer Res 66: 7390-7394.
7. He L, Hannon GJ, (2004) MicroRNAs: small RNAs with a big role in gene regulation. Nat Rev Genet 5: 522-531.
8. Calin GA, Croce CM, (2006) MicroRNA signatures in human cancers. Nat Rev Cancer 6: 857-866.
9. Chen CZ, (2005) MicroRNAs as oncogenes and tumor suppressors. N Engl J Med 353: 1768-1771.
10. Ventura A, Jacks T, (2009) MicroRNAs and cancer: short RNAs go a long way. Cell 136: 586-591.
11. Iorio MV, Ferracin M, Liu CG, Veronese A, Spizzo R, et al. (2005) MicroRNA gene expression deregulation in human breast cancer. Cancer Res 65: 7065-7070.
12. Volinia S, Calin GA, Liu CG, Ambs S, Cimmino A, et al. (2006) A microRNA expression signature of human solid tumors defines cancer gene targets. Proc Natl Acad Sci U S A 103: 2257-2261.
13. Blenkiron C, Goldstein LD, Thorne NP, Spiteri I, Chin SF, et al. (2007) MicroRNA expression profiling of human breast cancer identifies new markers of tumor subtype. Genome Biol 8: R214.
14. Enerly E, Steinfeld I, Kleivi K, Leivonen SK, Aure MR, et al. (2011) miRNA-mRNA integrated analysis reveals roles for miRNAs in primary breast tumors. PLoS One 6: e16915.
15. Chen X, Guo X, Zhang H, Xiang Y, Chen J, et al. (2009) Role of miR-143 targeting KRAS in colorectal tumorigenesis. Oncogene 28: 1385-1392.
16. Johnson SM, Grosshans H, Shingara J, Byrom M, Jarvis R, et al. (2005) RAS is regulated by the let-7 microRNA family. Cell 120: 635-647.
17. Yu S, Lu Z, Liu C, Meng Y, Ma Y, et al. (2010) miRNA-96 suppresses KRAS and functions as a tumor suppressor gene in pancreatic cancer. Cancer Res 70: 6015-6025.
18. Hanahan D, Weinberg RA, (2000) The hallmarks of cancer. Cell 100: 57-70.
19. Haagenson KK, Wu GS, (2010) The role of MAP kinases and MAP kinase phosphatase-1 in resistance to breast cancer treatment. Cancer metastasis reviews 29: 143-149.
20. Dunn KL, Espino PS, Drobic B, He S, Davie JR, (2005) The Ras-MAPK signal transduction pathway, cancer and chromatin remodeling. Biochemistry and cell biology = Biochimie et biologie cellulaire 83: 1-14.
21. Atanaskova N, Keshamouni VG, Krueger JS, Schwartz JA, Miller F, et al. (2002) MAP kinase/estrogen receptor cross-talk enhances estrogen-mediated signaling and tumor growth but does not confer tamoxifen resistance. Oncogene 21: 4000-4008.
22. Salh B, Marotta A, Matthewson C, Ahluwalia M, Flint J, et al. (1999) Investigation of the Mek-MAP kinase-Rsk pathway in human breast cancer. Anticancer research 19: 731-740.
23. Eckert LB, Repasky GA, Ulku AS, McFall A, Zhou H, et al. (2004) Involvement of Ras activation in human breast cancer cell signaling, invasion, and anoikis. Cancer Res 64: 4585-4592.
24. Lo HW, Hsu SC, Hung MC, (2006) EGFR signaling pathway in breast cancers: from traditional signal transduction to direct nuclear translocalization. Breast Cancer Res Treat 95: 211-218.
25. McCubrey JA, Steelman LS, Chappell WH, Abrams SL, Wong EW, et al. (2007) Roles of the Raf/MEK/ERK pathway in cell growth, malignant transformation and drug resistance. Biochim Biophys Acta 1773: 1263-1284.
26. Clark GJ, Der CJ, (1995) Aberrant function of the Ras signal transduction pathway in human breast cancer. Breast Cancer Res Treat 35: 133-144.
27. Koffa M, Malamoumitsi V, Agnantis N, Spandidos D, (1994) Mutational activation of k-ras oncogene in human breast-tumors. Int J Oncol 4: 573-576.
28. von Lintig FC, Dreilinger AD, Varki NM, Wallace AM, Casteel DE, et al. (2000) Ras activation in human breast cancer. Breast Cancer Res Treat 62: 51-62.
29. Spandidos DA, (1987) Oncogene activation in malignant transformation: a study of H-ras in human breast cancer. Anticancer research 7: 991-996.
30. Agnantis NJ, Constantinidou AE, Papaevagelou M, Apostolikas N, (1994) Comparative immunohistochemical study of ras-p21 oncoprotein in adenomatous hyperplasia and adenocarcinoma of the prostate gland. Anticancer Res 14: 2135-2140.
31. Kent OA, Chivukula RR, Mullendore M, Wentzel EA, Feldmann G, et al. (2010) Repression of the miR-143/145 cluster by oncogenic Ras initiates a tumor-promoting feed-forward pathway. Genes & development 24: 2754-2759.
32. Yu F, Deng H, Yao H, Liu Q, Su F, et al. (2010) Mir-30 reduction maintains self-renewal and inhibits apoptosis in breast tumor-initiating cells. Oncogene 29: 4194-4204.
33. Rodriguez-Gonzalez FG, Sieuwerts AM, Smid M, Look MP, Meijer-van Gelder ME, et al. (2011) MicroRNA-30c expression level is an independent predictor of clinical benefit of endocrine therapy in advanced estrogen receptor positive breast cancer. Breast cancer research and treatment 127: 43-51.
34. Lee CH, Subramanian S, Beck AH, Espinosa I, Senz J, et al. (2009) MicroRNA profiling of BRCA1/2 mutation-carrying and non-mutation-carrying high-grade serous carcinomas of ovary. PLoS One 4: e7314.
35. Morrissey ER, Diaz-Uriarte R, (2009) Pomelo II: finding differentially expressed genes. Nucleic Acids Res 37: W581-586.
36. Benjamini Y, Drai D, Elmer G, Kafkafi N, Golani I, (2001) Controlling the false discovery rate in behavior genetics research. Behav Brain Res 125: 279-284.
37. Zajac M, Moneo MV, Carnero A, Benitez J, Martinez-Delgado B, (2008) Mitotic catastrophe cell death induced by heat shock protein 90 inhibitor in BRCA1-deficient breast cancer cell lines. Mol Cancer Ther 7: 2358-2366.